Comparison of prostaglandin analogue, beta-blockers and prostaglandin analogue/beta-blockers fixed combination in patients with primary open-angle glaucoma

Hoxha, Gentian; Spahiu, Kelmend; Kaçaniku, Gazmend; Ismajli-Hoxha, Fëllanza; Ismaili, Mimoza

doi:10.1007/s00717-013-0189-y

Cited by 6 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, studies have shown that TTFC provides greater IOP reduction than its components travoprost and timolol, used separately as single agents [ 12 , 13 ]. The long-term IOP-lowering efficacy of TTFC has been proven in studies with up to 12 months of follow-up [ 18 , 22 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Tolerability of Travoprost 0.004%/Timolol 0.5%Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy

Lerner¹,

Park

Hubatsch

et al. 2017

Journal of Ophthalmology

View full text Add to dashboard Cite

Objective. To evaluate the efficacy and tolerability of travoprost 0.004%/timolol 0.5% fixed-dose combination (TTFC) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) inadequately controlled on beta-blocker monotherapy. Methods. In this phase IV, open-label study, 156 patients on beta-blocker monotherapy with mean intraocular pressure (IOP) between 18 and 32 mmHg were randomized (no washout period) to receive TTFC for 8 weeks (TTFC group) or to continue beta-blocker monotherapy for 4 weeks followed by TTFC for the remaining 4 weeks (beta-blocker group). Results. The mean IOP (±standard deviation) at baseline in the TTFC and beta-blocker groups was 22.5 ± 2.5 mmHg and 22.2 ± 2.3 mmHg, respectively, and at weeks 4 and 8, was 16.7 ± 3.1 mmHg and 16.1 ± 3.1 mmHg, respectively, in TTFC group and 21.1 ± 3.1 mmHg and 16.1 ± 2.8 mmHg, respectively, in the beta-blocker group. There was a significant least squares mean difference between TTFC and beta-blocker in 8 a.m. IOP at week 4 (−4.6 mmHg; one-sided 95% confidence interval [−inf, −3.9]; p < 0.0001 [primary endpoint]); the upper bound of the 95% confidence interval was within the prespecified limit (<0). Both treatments were well tolerated. Conclusion. Superior IOP control was achieved with TTFC in patients with OAG or OHT previously uncontrolled with beta-blockers. No new safety findings were identified. This trial is registered with ClinicalTrials.gov NCT02003391.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Tolerability of Travoprost 0.004%/Timolol 0.5%Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy

Lerner¹,

Park

Hubatsch

et al. 2017

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…The mean difference of IOP after 1 year (from first visit) in the patients of prostaglandin group was −6.8 mmHg (SD ± 2.2), in the patients of beta-blockers group was −4.6 mmHg (SD ± 1.8) and in the patients of prostaglandin/beta-blockersgroup was −7.9 mmHg (SD ± 1.9 mmHg). With Kruskal-Wallis test, there was statistically significant difference of IOP value in both eyes between first and seventh visit by groups (KW = 80.8, P < 0.0001)[17].…”

mentioning

confidence: 85%

Efficacy and Safety of Travoprost and Timolol Fixed Combination Compared to Travoprost in Patients with Primary Open Angle Glaucoma and Ocular Hypertension

Hoxha¹,

Spahiu²,

Kaçaniku³

et al. 2017

OJOph

Self Cite

View full text Add to dashboard Cite

Purpose: To compare intraocular pressure (IOP)-lowering efficacy and safety of travoprost 0.004% and travoprost 0.004% and beta-blocker 0.5% fixed combination ophthalmic solution in patients with open-angle glaucoma and ocular hypertension. Methods: In this prospective, multicentre clinical trial, 62 patients received travoprost 0.004% (n = 31) or travoprost 0.004% and beta-blocker 0.5% fixed combination (n = 31). Efficacy and safety were compared across treatment groups over 2 years. IOP reduction and adverse events were examined at 3, 6, 12 and 24 months for each group. Results: Mean IOP at the first visit in the travoprost 0.004% group was 26.4 (SD ± 2.1), and travoprost 0.004%/timolol 0.5% group was 26.3 (SD ± 2.1). Mean IOP after 24 months in the travoprost 0.004% group was 20.5 (SD ± 1.5) and travoprost 0.004%/timolol 0.5% group was 18.5 (SD ± 1.5). There were statistically significant differences in IOP in both eyes after third visit (after 1 year) and fourth visit (after 2 years). Conclusion: After 2 year of treatment, travoprost 0.004%/timolol 0.5% produced clinically relevant IOP reductions in patients with open-angle glaucoma or ocular hypertension that were greater than those produced by travoprost 0.004% alone.

show abstract

“…In the recent years, a new family of drugs called prostaglandin analogues has gain popularity for its remarkable IOP lowering ability. Unlike beta-blockers, Travoprost reduce IOP by increasing both uveoscleral and conventional aqueous humor outflow 13 .…”

Section: Introductionmentioning

confidence: 99%

The Effectivity of Levobunolol Versus Travoprost in Reducing Intraocular Pressure

Naz¹,

Faisal²,

iqbal³

et al. 2021

JMS

View full text Add to dashboard Cite

Objective: To compare levobunolol and travoprost for lowering the intra-ocular pressure (IOP) in patients of ocular hypertension and primary open-angle glaucoma. Materials and Methods: A Quasi experimental study was conducted in the ophthalmology department of Khyber Teaching Hospital, Peshawar. 120 patients of both genders and age between 18-80 years with ocular hypertension or primary open angle glaucoma requiring single pressure lowering drug were enrolled in the study. Subjects were divided into two groups (60 in each). One group was treated with travoprost eye drops (0.004%, OD) while other group with levobunolol eye drops (0.5%, OD). After initial screening visit where demographic data and baseline IOP was recorded on structured proforma, three follow-up visits were arranged each at 02 weeks interval. At each follow-up visit, IOP was recorded by standard protocols to evaluate and compare the ocular hypotensive efficacy of study drugs by calculating mean IOP change from the baseline. Only patients with no missing IOP measurements for all visits were considered eligible for the efficacy evaluation. Results: A total of 120 patients were observed having age range from 18 years and above with mean age 52.16 ± 9.56 and predominance of male gender. Upon comparative analysis, no significant statistical difference (p value >0.05) was observed in the ocular hypotensive efficacy of levobunolol and travoprost measured at each follow-up visit, indicating both the drugs equally effective. Moreover, age groups did not reveal any significant statistical impact on the treatment outcome of patients treated with either study drug. Conclusion: Though both the drugs are equally effective, levobunolol is better option than travoprost for the treatment of glaucoma because of its fast onset of action, cost effectiveness and easy availability.

show abstract

Comparison of prostaglandin analogue, beta-blockers and prostaglandin analogue/beta-blockers fixed combination in patients with primary open-angle glaucoma

Cited by 6 publications

References 22 publications

Efficacy and Tolerability of Travoprost 0.004%/Timolol 0.5%Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy

Efficacy and Tolerability of Travoprost 0.004%/Timolol 0.5%Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy

Efficacy and Safety of Travoprost and Timolol Fixed Combination Compared to Travoprost in Patients with Primary Open Angle Glaucoma and Ocular Hypertension

The Effectivity of Levobunolol Versus Travoprost in Reducing Intraocular Pressure

Contact Info

Product

Resources

About